TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 80 lat
- •Świeżo rozpoznany glejak mózgu (potwierdzony badaniem histologicznym) bez mutacji IDH
- •Glejak o charakterystycznym kształcie motyla - tumor rozciągający się na obie strony mózgu przez jego centralną część
- •Pacjent nie rozpoczął jeszcze standardowego leczenia (chemioterapii i radioterapii)
- •Prawidłowe wyniki badań krwi dotyczące liczby komórek, wątroby i nerek
- •Prawidłowe parametry krzepnięcia krwi
- •Gotowość do uczestnictwa w badaniu i podpisanie świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Dent Neurologic Institute
Buffalo, United States
Trial contact
Ann-Marie Hulstine
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.